Telmisartan

Generic Name: Telmisartan

Brand Names: Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₀N_₄O_₂

CAS Number: 144701-48-4

Unique Ingredient Identifier: U5SYW473RQ

Background: Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.

Indication: Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension

Clinical Trials

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Completed

Conditions: Hypertension

Interventions: Drug: Ramipril
Drug: Telmisartan

First Posted Date: 2020-04-21

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 63744

Registration Number: NCT04354350

Locations: 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States

Telmisartan for Treatment of COVID-19 Patients

Phase 4

Completed

Conditions: COVID-19 Drug Treatment

Interventions: Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.

First Posted Date: 2020-04-21

Last Posted Date: 2020-12-24

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 400

Registration Number: NCT04355936

Locations: 🇦🇷
Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷
Hospital Español de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

Completed

Conditions: Hypertension

Interventions: Drug: Loop diuretics, thiazides, dihydropyridines
Drug: Telmisartan

First Posted Date: 2020-04-21

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 40048

Registration Number: NCT04354376

Locations: 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Hypertension,Essential

Interventions: Drug: Telmisartan
Drug: Amlodipine high
Drug: AD209
Drug: Amlodipine low

First Posted Date: 2020-01-06

Last Posted Date: 2021-07-21

Lead Sponsor: Addpharma Inc.

Target Recruit Count: 176

Registration Number: NCT04218552

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

Phase 3

Completed

Conditions: Hypertension
Hypercholesterolemia

Interventions: Drug: Ezetimibe/Rosuvastatin
Drug: Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET
Drug: Telmisartan

First Posted Date: 2019-11-08

Last Posted Date: 2021-05-12

Lead Sponsor: Addpharma Inc.

Target Recruit Count: 131

Registration Number: NCT04158076

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Improving 24-hour Blood Pressure in Obstructive Sleep Apnea

Early Phase 1

Withdrawn

Conditions: Obstructive Sleep Apnea

Interventions: Device: Continuous Positive Airway Pressure CPAP
Drug: Telmisartan 80mg
Other: Microcrystalline Cellulose
Dietary Supplement: Alpha-Lipoic Acid 600mg